These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 37809646)

  • 21. Coverage of Coronavirus Disease-2019 (COVID-19) Booster Dose (Precautionary) in the Adult Population: An Online Survey.
    Masthi Nr R; Brahmajosyula A; Khamar A; Acharya N; Bilichod LP; Kondath D
    Cureus; 2022 Jul; 14(7):e26912. PubMed ID: 35983381
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Severe acute respiratory syndrome coronavirus-2 antibody response after Moderna vaccine booster on healthcare providers.
    Fachrucha F; Sutoyo DK; Nurwidya F; Andarini SL; Susanto AD; Isbaniah F; Handayani D; Yunus F; Soehardiman D; Zaini J; Saputri S; Prasenohadi
    J Infect Dev Ctries; 2023 May; 17(5):617-622. PubMed ID: 37279427
    [TBL] [Abstract][Full Text] [Related]  

  • 23. T-Cell Mediated Response after Primary and Booster SARS-CoV-2 Messenger RNA Vaccination in Nursing Home Residents.
    Schiavoni I; Palmieri A; Olivetta E; Leone P; Di Lonardo A; Mazzoli A; Cafariello C; Malara A; Palamara AT; Incalzi RA; Onder G; Stefanelli P; Fedele G;
    J Am Med Dir Assoc; 2023 Feb; 24(2):140-147.e2. PubMed ID: 36587928
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Targeted Vaccine Allocation Could Increase the COVID-19 Vaccine Benefits Amidst Its Lack of Availability: A Mathematical Modeling Study in Indonesia.
    Fuady A; Nuraini N; Sukandar KK; Lestari BW
    Vaccines (Basel); 2021 May; 9(5):. PubMed ID: 34066317
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Uncovering inequities in Covid-19 vaccine coverage for adults and elderly in Brazil: A multilevel study of 2021-2022 data.
    Boing AF; Boing AC; Barberia L; Borges ME; Subramanian SV
    Vaccine; 2023 Jun; 41(26):3937-3945. PubMed ID: 37221119
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Study of efficacy and longevity of immune response to third and fourth doses of COVID-19 vaccines in patients with cancer: A single arm clinical trial.
    Thakkar A; Pradhan K; Duva B; Carreno JM; Sahu S; Thiruthuvanathan V; Campbell S; Gallego S; Bhagat TD; Rivera J; Choudhary G; Olea R; Sabalza M; Shapiro LC; Lee M; Quinn R; Mantzaris I; Chu E; Will B; Pirofski LA; Krammer F; Verma A; Halmos B
    Elife; 2023 Mar; 12():. PubMed ID: 36975207
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Predictors of second COVID-19 booster dose or new COVID-19 vaccine hesitancy among nurses: A cross-sectional study.
    Galanis P; Vraka I; Katsiroumpa A; Siskou O; Konstantakopoulou O; Katsoulas T; Mariolis-Sapsakos T; Kaitelidou D
    J Clin Nurs; 2023 Jul; 32(13-14):3943-3953. PubMed ID: 36345133
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effectiveness of mRNA COVID-19 Vaccine Boosters Against Infection, Hospitalization, and Death: A Target Trial Emulation in the Omicron (B.1.1.529) Variant Era.
    Ioannou GN; Bohnert ASB; O'Hare AM; Boyko EJ; Maciejewski ML; Smith VA; Bowling CB; Viglianti E; Iwashyna TJ; Hynes DM; Berry K;
    Ann Intern Med; 2022 Dec; 175(12):1693-1706. PubMed ID: 36215715
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Side Effects after mRNA COVID-19 Vaccine as a Booster in Health Workers.
    Pakki TR; Mariana N; Tampubolon ML; Rusli A; Romadhona S; Intan AD; Chohan Z; Widiantari AD; Herlina H; Puspitasari A; Mahardika M; Suliati S; Maemun S; Murtiani F; Syahril M
    Iran J Public Health; 2022 Nov; 51(11):2504-2509. PubMed ID: 36561250
    [TBL] [Abstract][Full Text] [Related]  

  • 30. COVID-19 lateral flow IgG seropositivity and serum neutralising antibody responses after primary and booster vaccinations in Chile: a cross-sectional study.
    Sauré D; O'Ryan M; Torres JP; Zuñiga M; Soto-Rifo R; Valiente-Echeverría F; Gaete-Argel A; Neira I; Saavedra V; Acevedo ML; Archila C; Acuña F; Rain M; Basso LJ
    Lancet Microbe; 2023 Mar; 4(3):e149-e158. PubMed ID: 36716754
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The effectiveness of the first dose COVID-19 booster vs. full vaccination to prevent SARS-CoV-2 infection and severe COVID-19 clinical event: a meta-analysis and systematic review of longitudinal studies.
    Xu J; Lan X; Zhang L; Zhang X; Zhang J; Song M; Liu J
    Front Public Health; 2023; 11():1165611. PubMed ID: 37325336
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Informing rubella vaccination strategies in East Java, Indonesia through transmission modelling.
    Wu Y; Wood J; Khandaker G; Waddington C; Snelling T
    Vaccine; 2016 Nov; 34(46):5636-5642. PubMed ID: 27670077
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effectiveness of BNT162b2 and CoronaVac COVID-19 vaccination against asymptomatic and symptomatic infection of SARS-CoV-2 omicron BA.2 in Hong Kong: a prospective cohort study.
    Tsang NNY; So HC; Cowling BJ; Leung GM; Ip DKM
    Lancet Infect Dis; 2023 Apr; 23(4):421-434. PubMed ID: 36521506
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Relationship between primary vaccination coverage and booster coverage against COVID-19, socio-economic indicators, and healthcare structure in Brazil.
    Martins-Filho PR; Rocha Santana RR; Barberia LG; Santos VS
    Public Health; 2023 Jul; 220():108-111. PubMed ID: 37295273
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Coverage of primary and booster vaccination against COVID-19 by socioeconomic level: A nationwide cross-sectional registry study.
    Hansen BT; Labberton AS; Kour P; Kraft KB
    Hum Vaccin Immunother; 2023 Dec; 19(1):2188857. PubMed ID: 36941785
    [TBL] [Abstract][Full Text] [Related]  

  • 36. COVID-19 Booster Dose Coverage and Hesitancy among Older Adults in an Urban Slum and Resettlement Colony in Delhi, India.
    Sharma N; Basu S; Lalwani H; Rao S; Malik M; Garg S; Shrivastava R; Singh MM
    Vaccines (Basel); 2023 Jun; 11(7):. PubMed ID: 37514993
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evaluation of the safety and immunogenicity of different COVID-19 vaccine combinations in healthy individuals: study protocol for a randomized, subject-blinded, controlled phase 3 trial [PRIBIVAC].
    Poh XY; Lee IR; Lim C; Teo J; Rao S; Chia PY; Ong SWX; Lee TH; Lin RJH; Ng LFP; Ren EC; Lin RTP; Wang LF; Renia L; Lye DC; Young BE
    Trials; 2022 Jun; 23(1):498. PubMed ID: 35710572
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Immunogenicity and effectiveness of COVID-19 booster vaccination among people living with HIV: a systematic review and meta-analysis.
    Cheng MQ; Li R; Weng ZY; Song G
    Front Med (Lausanne); 2023; 10():1275843. PubMed ID: 37877024
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Longer-term effectiveness of a heterologous coronavirus disease 2019 (COVID-19) vaccine booster in healthcare workers in Brazil.
    Marra AR; Miraglia JL; Malheiro DT; Guozhang Y; Teich VD; Victor EDS; Pinho JRR; Cypriano A; Vieira LW; Polonio M; Ornelas RH; de Oliveira SM; Borges FA; Oler SCC; Ricardo VCV; Maezato AM; Callado GY; Schettino GPP; de Oliveira KG; Santana RAF; Malta FM; Amgarten D; Boechat AL; Kobayashi T; Salinas JL; Edmond MB; Rizzo LV
    Antimicrob Steward Healthc Epidemiol; 2023; 3(1):e104. PubMed ID: 37396193
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of BNT162b2 booster dose on anti-SARS-CoV-2 spike trimeric IgG antibodies in seronegative individuals.
    Salvagno GL; Henry BM; Pighi L; De Nitto S; Gianfilippi G; Lippi G
    Clin Chem Lab Med; 2022 May; 60(6):930-933. PubMed ID: 35303764
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.